Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Conditions
Interventions
NRP104
Locations
48
United States
Clinical Study Centers, LLC
Little Rock, Arkansas, United States
Valley Clinical Research, Inc.
El Centro, California, United States
University of California, Irvine Child Development Center
Irvine, California, United States
Bay Area Research Institute
Lafayette, California, United States
Peninsula Research Associates
Rolling Hills Estate, California, United States
University of California, San Francisco, Dept. of Psychiatry
San Francisco, California, United States
Start Date
May 1, 2006
Completion Date
November 1, 2006
Last Updated
July 2, 2009
NCT07189442
NCT06123741
NCT06847165
NCT04175041
NCT07459699
NCT07439276
Lead Sponsor
New River Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions